Azoganstrisin is a monoclonal antibody being investigated as a potential treatment for certain types of cancer, particularly in patients with solid tumors. It works by targeting specific proteins on cancer cells, aiming to enhance the immune system's ability to recognize and destroy these cells. Clinical trials are ongoing to evaluate its safety, efficacy, and potential applications in oncology.